Sumitomo Mitsui Trust Group Inc. increased its stake in shares of Moderna, Inc. (NASDAQ:MRNA – Free Report) by 187.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 59,590 shares of the company’s stock after purchasing an additional 38,833 shares during the quarter. Sumitomo Mitsui Trust Group Inc.’s holdings in Moderna were worth $11,475,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in shares of Moderna during the 2nd quarter worth about $2,142,877,000. Theleme Partners LLP purchased a new position in Moderna in the second quarter valued at approximately $564,272,000. Wellington Management Group LLP lifted its holdings in shares of Moderna by 4.4% during the 2nd quarter. Wellington Management Group LLP now owns 2,461,574 shares of the company’s stock valued at $172,384,000 after acquiring an additional 103,977 shares in the last quarter. First Trust Advisors LP boosted its position in shares of Moderna by 59.3% in the first quarter. First Trust Advisors LP now owns 2,392,693 shares of the company’s stock worth $121,549,000 after buying an additional 891,072 shares during the period. Finally, Merck & Co. Inc. purchased a new position in Moderna in the 2nd quarter worth approximately $161,642,545. 75.33% of the stock is currently owned by hedge funds and other institutional investors.
Moderna Stock Performance
NASDAQ:MRNA traded up $12.73 during midday trading on Friday, reaching $254.19. 16,295,043 shares of the company traded hands, compared to its average volume of 18,981,452. The firm has a market capitalization of $101.48 billion, a price-to-earnings ratio of -31.81 and a beta of 1.16. The company has a fifty day moving average price of $191.85 and a 200 day moving average price of $91.51. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.29 and a quick ratio of 2.18. Moderna, Inc. has a twelve month low of $22.28 and a twelve month high of $267.50.
Moderna (NASDAQ:MRNA – Get Free Report) last issued its earnings results on Friday, November 6th. The company reported $0.38 earnings per share for the quarter, topping the consensus estimate of ($1.10) by $1.48. The firm had revenue of $1.31 billion for the quarter, compared to analyst estimates of $890.25 million. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%. The firm’s revenue for the quarter was up 29.2% on a year-over-year basis. During the same period last year, the company earned ($0.51) earnings per share. On average, analysts expect that Moderna, Inc. will post -6.11 EPS for the current fiscal year.
Key Moderna News
Here are the key news stories impacting Moderna this week:
- Positive Sentiment: Moderna reported third-quarter revenue of $1.31 billion, up 29.2% year over year, and earnings of $0.38 per share, far ahead of analysts’ expectations for a loss. Stronger overseas COVID-19 vaccine sales helped drive the results. Reuters report on revenue and demand
- Positive Sentiment: Management raised its 2026 revenue-growth forecast to 15%–25%, from a prior outlook of up to 10%. The company also said it plans to reduce research and development spending, supporting its near-term financial performance. CNBC outlook report
- Positive Sentiment: Health Canada authorized Moderna’s seasonal flu and flu-COVID combination vaccines for adults 50 and older, opening a potential new market for its mRNA products. CBC report on Canadian approvals
- Positive Sentiment: Investors are also watching prospects for Moderna’s cancer vaccine: CEO Stéphane Bancel said it could have potential beyond melanoma. That adds pipeline excitement, though future commercial value remains uncertain. Yahoo Finance report on cancer vaccine prospects
- Neutral Sentiment: Moderna and GSK settled a patent dispute involving Moderna’s COVID and RSV shots. The settlement removes a source of legal uncertainty, but the available report does not specify its financial terms. Reuters report on patent settlement
- Negative Sentiment: The sharp rally has heightened concerns that expectations for the cancer-vaccine pipeline may be running ahead of near-term revenue potential. Moderna’s longer-term prospects still depend on sustaining vaccine sales and turning pipeline advances into commercial products. Barron’s analysis of Moderna’s earnings and valuation
Analyst Upgrades and Downgrades
MRNA has been the topic of a number of analyst reports. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $130.00 target price on shares of Moderna in a research report on Wednesday, August 19th. Loop Capital set a $135.00 price objective on shares of Moderna in a report on Wednesday, August 19th. Citigroup reiterated a “sell” rating on shares of Moderna in a research note on Friday, October 23rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Moderna in a report on Wednesday, September 9th. Finally, The Goldman Sachs Group raised their price target on shares of Moderna from $120.00 to $137.00 and gave the stock a “neutral” rating in a research report on Thursday, October 15th. Six equities research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and four have issued a Sell rating to the company’s stock. According to MarketBeat, Moderna currently has an average rating of “Hold” and an average price target of $107.10.
Get Our Latest Research Report on Moderna
Insider Buying and Selling
In other Moderna news, President Stephen Hoge sold 39,145 shares of the business’s stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $220.72, for a total transaction of $8,640,084.40. Following the completion of the transaction, the president directly owned 1,636,565 shares of the company’s stock, valued at $361,222,626.80. The trade was a 2.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO James M. Mock sold 34,836 shares of the company’s stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $134.49, for a total transaction of $4,685,093.64. Following the completion of the transaction, the chief financial officer owned 59,375 shares of the company’s stock, valued at approximately $7,985,343.75. This trade represents a 36.98% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 197,251 shares of company stock valued at $33,875,904 in the last quarter. Company insiders own 10.80% of the company’s stock.
Moderna Company Profile
Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease.
The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases.
Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.
Featured Articles
- Five stocks we like better than Moderna
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA – Free Report).
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.
